Literature DB >> 17689283

Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.

Ernest C Borden1.   

Abstract

Increased expression of genes, silenced by methylation of their promoters, could have relevance for increasing effects of not only interferons (IFNs) but also APO2L/TRAIL, cytotoxics and immunotherapeutics for melanoma and other malignancies. A resistant melanoma cell line, A375, lacked APO2L/TRAIL or apoptosis induction by either IFN-alpha2 or IFN-beta. However, apoptosis was induced by IFNs in A375 cells by 5-aza,2'-deoxycytidine (5-Aza-dC), evaluated based upon the postulate that promoter methylation might be silencing pro-apopoptotic IFN-stimulated genes (ISGs). RASSF1A, commonly methylated at high frequency in many tumors including melanoma, which we discovered to be also an IFN-regulated gene, was increased by 5-Aza-dC. RASSF1A was important in enhancing apoptotic effects of not only IFNs and APO2L/TRAIL but also cisplatin. Unraveling epigenetic regulatory mechanisms, as yet only partially identified, will result in new biological insights and improved strategies for therapeutic use of IFNs or ISGs such as APO2L/TRAIL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689283      PMCID: PMC2682546          DOI: 10.1016/j.cytogfr.2007.06.022

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  116 in total

1.  RASSF1A, the new guardian of mitosis.

Authors:  Endre Máthé
Journal:  Nat Genet       Date:  2004-02       Impact factor: 38.330

Review 2.  Response and resistance to interferons and interacting cytokines.

Authors:  E C Borden; J Waalen; R Schreiber; B Williams
Journal:  J Natl Cancer Inst       Date:  1995-02-15       Impact factor: 13.506

Review 3.  An overview of the interferon system: signal transduction and mechanisms of action.

Authors:  D V Kalvakolanu; E C Borden
Journal:  Cancer Invest       Date:  1996       Impact factor: 2.176

4.  Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.

Authors:  O I Olopade; D L Buchhagen; K Malik; J Sherman; T Nobori; S Bader; M M Nau; A F Gazdar; J D Minna; M O Diaz
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

5.  Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma.

Authors:  E A Holland; S C Beaton; B G Edwards; R F Kefford; G J Mann
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

6.  Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.

Authors:  Douglas W Leaman; Mamta Chawla-Sarkar; Barbara Jacobs; Keyur Vyas; Yaping Sun; Aylin Ozdemir; Taolin Yi; Bryan R Williams; Ernest C Borden
Journal:  J Interferon Cytokine Res       Date:  2003-12       Impact factor: 2.607

7.  Immunoregulatory properties of ISG15, an interferon-induced cytokine.

Authors:  J D'Cunha; E Knight; A L Haas; R L Truitt; E C Borden
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex.

Authors:  Min Sup Song; Su Jeong Song; Nagi G Ayad; Jin Sook Chang; Joo Hyun Lee; Hyun Kyung Hong; Ho Lee; Naeyun Choi; Jhingook Kim; Hojoong Kim; Jin Woo Kim; Eui-Ju Choi; Marc W Kirschner; Dae-Sik Lim
Journal:  Nat Cell Biol       Date:  2004-01-25       Impact factor: 28.824

9.  Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.

Authors:  W M Stadler; J Sherman; S K Bohlander; D Roulston; M Dreyling; D Rukstalis; O I Olopade
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

10.  Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction.

Authors:  P Cairns; K Tokino; Y Eby; D Sidransky
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

View more
  5 in total

1.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

2.  Breast Tumor-Associated Metalloproteases Restrict Reovirus Oncolysis by Cleaving the σ1 Cell Attachment Protein and Can Be Overcome by Mutation of σ1.

Authors:  Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

3.  Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.

Authors:  Ruth Halaban; Michael Krauthammer; Mattia Pelizzola; Elaine Cheng; Daniela Kovacs; Mario Sznol; Stephan Ariyan; Deepak Narayan; Antonella Bacchiocchi; Annette Molinaro; Yuval Kluger; Min Deng; Nam Tran; Wengeng Zhang; Mauro Picardo; Jan J Enghild
Journal:  PLoS One       Date:  2009-02-23       Impact factor: 3.240

Review 4.  Exploiting tumor epigenetics to improve oncolytic virotherapy.

Authors:  Nicole E Forbes; Hesham Abdelbary; Mathieu Lupien; John C Bell; Jean-Simon Diallo
Journal:  Front Genet       Date:  2013-09-20       Impact factor: 4.599

Review 5.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.